Table 1 Baseline characteristics of the modified intention-to-treat population from study MS-F203
Characteristic | All patients | Placebo | Dalfampridine-ER 10 mg BID | P-value |
|---|---|---|---|---|
(N = 296) | (N = 72) | (N = 224) | ||
Age, years (mean ± SE) | 51.4 ± 0.51 | 50.9 ± 1.05 | 51.5 ± 0.58 | 0.50 |
Female gender, n (%) | 201 (67.9) | 43 (59.7) | 158 (70.5) | 0.11 |
MS Diagnosis Type | 0.52 | |||
Primary progressive | 44 (14.9) | 14 (19.4) | 30 (13.4) | |
Progressive relapsing | 12 (4.1) | 2 (2.8) | 10 (4.5) | |
Relapsing remitting | 82 (27.7) | 21 (29.2) | 61 (27.2) | |
Secondary progressive | 158 (53.4) | 35 (48.6) | 123 (54.9) | |
Disease Duration, years (mean ± SE) | 13.4 ± 0.48 | 12.7 ± 0.97 | 13.6 ± 0.55 | 0.38 |
EDSS score (mean ± SE) | 5.8 ± 0.06 | 5.8 ± 0.13 | 5.8 ± 0.07 | 0.85 |
Range (Minimum, Maximum) | (3, 7) | (3, 7) | (3, 7) | |
Timed 25-Foot Walk speed, feet/second (mean ± SE) | 2.1 ± 0.04 | 2.1 ± 0.08 | 2.1 ± 0.05 | 0.85 |